I was doing this last year to great success. Around October 2021...

First 2505 Last

Share
Profile

Follow
Jezzaaa

792 Posts.

1827

25/11/22

10:04

Post #: 64982032
Share

Originally posted by Simoncho ↑

If you take the time to understand TA it makes sense, but nobody is going to sit you down and talk you through it. Even if they did, it wouldn't make much sense until you sit down and watch how it plays out. It would be like learning to surf or fish from a textbook.

If you assume that gaps up happen suddenly and spontaneously (which is observable), and that it's either coming from excited holders or unresesearched new holders jumping onto a "good thing" (which is logical), then it's more in short-term than long-term interest. People will hold while it's going up but be quicker than normal to sell up if the profit is disappearing and, with greater urgency, if the new shares look like falling into the red. "The red" will be unusually based on the gap as it's the top end of the gap that the new money started buying.

If you keep your mouth shut and your eyes open, you can increase your holding without putting in more of your hard-earned or take back your capital without give up any shares. If pip trading seems silly, think about trading 200,000 shares, when each pip is worth $1000.

Each to their own.

Expand

I was doing this last year to great success. Around October 2021 actually. Everyone on the forum said 12,000 approvals were coming any day now and tried to make me feel bad for my decision. That was a year ago.... Half my holdings came from "free shares" by getting in and out on obvious TA indicators. Now -- millionaire at 27.

But genuinely though... Things are getting a little close now, not sure I'd be game with things so close. Good on ya.

Last edited by Jezzaaa: 25/11/22

AGY Price at posting: 61.5¢ Sentiment: Buy Disclosure: Held
16 Upvote

1 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 278 more messages in this thread...

First 2505 Last

Add AGY (ASX) to my watchlist

(20min delay)
Last 3.9¢		Change 0.001(2.63%)		Mkt cap ! $56.78M

Open	High	Low	Value	Volume
4.0¢	4.1¢	3.9¢	$303.9K	7.541M

Buyers (Bids)

No.	Vol.	Price($)
3	304999	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	25000	1

View Market Depth

No.	Vol.	Price($)
3	304999	0.039
7	563206	0.038
5	648648	0.037
22	2110708	0.036
25	2513178	0.035

Price($)	Vol.	No.
0.040	25000	1
0.041	406425	2
0.042	751292	7
0.043	1956941	3
0.044	1035285	9

Last trade - 16.10pm 07/10/2024 (20 minute delay)

AGY (ASX) Chart

I was doing this last year to great success. Around October 2021...

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I was doing this last year to great success. Around October 2021...

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News